Lv1
56 积分 2022-12-29 加入
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
2天前
已完结
TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative, early or locally advanced breast cancer: a multicenter, randomized, double-blind, parallel-controlled, phase III equivalence trial
29天前
已完结
Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study
1个月前
已完结
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression
1个月前
已完结
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial
2个月前
已完结
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
4个月前
已完结
Gastruloids enable modeling of the earliest stages of human cardiac and hepatic vascularization
6个月前
已完结
Genomic frontiers in congenital heart disease
8个月前
已完结
LBA25 Culmerciclib plus fulvestrant as first-line treatment for HR+/HER2- advanced breast cancer: A phase III trial (CULMINATE-2)
10个月前
已关闭
New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists
10个月前
已完结
皖公网安备34019202002308
